Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06640361 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Olverembatinib in SDH-deficient GIST.

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Re-verified, no change to tracked fieldsv3
  2. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Oct 2024 to Nov 11, 2024 · Site details revisedv2 Show 2 more changesShow less
    • Start date changed from estimate of Oct 2024 to Nov 11, 2024
    • Site details revised
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
An international multicenter, open, single-arm pivotal registration phase III study to determine the efficacy and safety of olverembatinib in patients with SDH-deficient gastrointestinal stromal tumor (GIST) who have previously been treated with one-line therapy, and to evaluate the progression-free survival and clinical benefit rate of olverembatinib in patients with SDH-deficient GIST.
Trial Details
NCT Number NCT06640361
Lead Sponsor Ascentage Pharma Group Inc.
Collaborators: HealthQuest Pharma Inc.
Conditions GIST
Enrollment 40 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov